Arixtra fondaparinux: Phase III; marketed to prevent VE in patients undergoing hip refractory surgery, hip replacement surgery, or knee replacement surgery

In the international, double-blind, placebo-controlled Phase III ARTEMIS trial in 849 patients, the incidence of VE was 5.6%

Read the full 180 word article

How to gain access

Continue reading with a
two-week free trial.